中文摘要：

目的：为我国完善基本药物集中招标采购制度提供参考。方法：对四川省卫生厅公布的2011年1～4批基本药物集中招标中标品种的品规、企业、价格等进行统计分析。结果：四川省卫生厅先后发布4批871个品规的基本药物集中招标采购中标品种,其中有34个目录内药物品种没有中标,涉及中标企业354个,企业中标品规1～28个不等。化学药中标价为0.07～52.7元,中位价为2.5元;中成药中标价为0.18～84元,中位价为7.5元;中标价最低为零售指导价的1/20.1,最高为零售指导价的1/1.2。结论：四川省基本药物中标品种及企业分布相对较合理;目录品种不适宜等原因导致品规未中标;中标价过低将导致国家基本药物制度难以长效实施。建议建立国家基本药物制度长效机制,制定适宜增补品种及合理招标采购方案。

英文摘要：

OBJECTIVE：To provide reference for the improvement of centralized bidding and purchase system of essential drugs.METHODS：1～4 batches of the bidding essential drugs announced on the website of Sichuan provincial health department were analyzed statistically in terms of specification,manufacturers and prices.RESULTS：1～4 batches of bidding drugs including 871 specifications were announced by Sichuan provincial health department in 2011.34 drugs in essential drug list（EML）lost the bid,354 manufacturers won the bid,the bidding number varied from1 to 28.The price of bidding chemical drugs ranged 0.07～ 52.7 yuan with medium price of 2.5 yuan,Chinese patent drugs 0.18～84 yuan with medium price of 7.5 yuan.The lowest price of bidding drug was only 1/20.1 of government referential price,and the highest was 1/1.2 of referential price.CONCLUSION：Variety and enterprise distribution of bidding essential drugs are reasonable in Sichuan province relatively;inappropriate EML and other reasons result in lost the bid.The unreasonable low price of bidding drugs would lead to the difficulty of long-term implementation of nation essential drug system.It is suggested to establish long-term mechanism of essential drug system and formulate suitable supplemental variety and reasonable bidding and purchase plan.